How CRO Strategic Account Teams Expand Business in the Age of Consolidation

How CRO Strategic Account Teams Expand Business in the Age of Consolidation

The contract research market is consolidating, and the largest providers are getting larger. For a mid-tier CRO trying to grow inside the same pharma and biotech sponsors, that can feel like the ground is closing. The opening it creates is easy to miss, and it sits in the difference between two words: wider and deeper.

What consolidation is actually doing

Pharma sponsors have spent the last several years reducing the number of providers they work with. Most large sponsors now route the majority of their clinical work through a short list of preferred CROs. One industry analysis in Pharmaceutical Technology estimated that at many global pharma companies, just two or three preferred providers receive as much as 80% of the available contract clinical-research work, with the rest going to CROs that hold specialty capabilities.

The largest CROs have built their growth on that model. IQVIA reported an R&D Solutions backlog of $32.7 billion at the end of 2025; ICON reported a backlog of $24.7 billion at the end of 2024. These are enormous positions inside the world's biggest drug developers, and they keep expanding as sponsors consolidate more scope onto fewer names.

That expansion has a specific shape. As a top CRO wins more of a sponsor's work, it gets wider inside the account: more programs, more therapeutic areas, more functions, more sites under one master agreement. Width is what the preferred-provider model rewards and what the backlog numbers measure.

Wider is not deeper

Width and depth are different things, and the difference is where a mid-tier CRO finds room.

Width is how much of the account a provider covers. Depth is how strong the relationship is at each point of that coverage: whether the provider has a real relationship with the people who decide the sponsor's pipeline strategy, whether procurement sees them as a partner or a line item, whether the medical and clinical-development teams trust them with the assets that matter most, whether anyone above the program team would defend the relationship in a portfolio review.

A provider can be very wide and still be thin in those places. Covering a dozen of a sponsor's studies does not, by itself, mean the provider has depth with the people who will shape the next ten. And depth is where strategic partnerships are actually built, because a strategic partnership is a relationship a sponsor protects when the next decision comes, not simply a vendor that currently holds a lot of work.

This is the gap consolidation leaves. The largest CROs are rewarded for getting wider, and width does not guarantee depth across every relationship inside a sprawling account. Somewhere in a giant incumbent's footprint are the programs, the functions, and the decision-makers where the relationship is shallow, where the work is being delivered but the partnership underneath it is not strong.

Why a mid-tier CRO can win the depth game

A mid-tier CRO is built to compete on exactly the thing the giants struggle to guarantee. It can move faster, decide faster, and concentrate its expertise in a few therapeutic areas rather than spreading across all of them. In the areas it has chosen, a focused mid-tier provider can offer depth of specialization that a generalist covering everything cannot match.

That depth matters most where sponsors feel the most pain. Patient recruitment and study timelines are the problems that decide whether a program lands on schedule. Industry research has long found that roughly 80% of clinical trials miss their original enrollment timelines, and the Tufts Center for the Study of Drug Development estimated in 2024 that the direct cost of a Phase III trial averages about $55,700 per day, which makes every week of delay a six-figure problem before any lost commercial value is counted. A mid-tier CRO that can build a genuine reputation for solving recruitment and timeline risk in its chosen therapeutic areas is building depth on the dimension sponsors care about most.

That reputation, focused and specific, is how a smaller provider becomes the partner a sponsor trusts with a program, rather than one more name that could deliver it.

Find the gaps, then work them

The opening is real, but it does not convert by working harder inside the same proposals. Expanding into a giant pharma or biotech account means knowing where the incumbent's coverage is wide and its relationship is thin, and then building depth in that specific place.

That starts with a clear read on each target account. Where does the incumbent actually have strong relationships, and where is it merely delivering work. Which decision-makers shape the sponsor's pipeline, and which of them has no real relationship with any provider but the default incumbent. Where do the sponsor's most at-risk programs sit, and do they fall in the therapeutic areas where a mid-tier provider has earned the right to be trusted. These are knowable things about a specific account, and they turn a vague ambition to grow into a prioritized plan a team can work.

Where Vitality Index fits

The hard part is seeing the account clearly enough to know where the depth gaps are and which ones are worth pursuing. A strategic account team carrying a full set of sponsor relationships rarely has a structured read on where each account stands or where the incumbent is exposed.

At Match Vertical Partners, we built the Vitality Index to give CRO strategic account teams that read. It assesses where a provider stands inside a sponsor account across seven areas of the relationship, produces a baseline score that shows where the account is strong and where it is shallow, and turns that into a prioritized pursuit plan the team can actively sell against. In a market where the largest providers are growing wider, the mid-tier teams that can find and build depth are the ones positioned to take strategic share.

See the Vitality Index applied to your accounts. Schedule a 30-minute demo.